Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1989-6-30
|
pubmed:abstractText |
To assess pharmacodynamic and pharmacokinetic properties of acute, subchronic and withdrawn quazepam, a single-blind, longitudinal study was run in eight male, healthy young volunteers. The design covered a 1-week placebo run-in period, a period with daily oral night-time administration of 15 mg quazepam until a pharmacokinetic steady-state was reached (3 weeks) and a 2-week placebo withdrawal period. Oculodynamic Test (ODT) (EOG-registration with simultaneous choice reaction task, CRT) and Adaptive Pursuit Tracking Test (APTT) were used for assessment of intradiurnal and long-term profiles of attention, perception, cognition, objective sedation, psychomotor and muscular (force-related) parameters and cardiorespiratory measures under workload. Visual analogue scales (VAS) of sedation, excitation and state anxiety were applied additionally. Plasma levels of quazepam and its metabolites (oxoquazepam and desalkyl-oxoquazepam) were intermittently analyzed by GC, within 24 h after actual blood sampling in the morning of assessment days, to check the attainment of the intended criterion for termination of medication (steady-state, "on-line kinetic procedure"). Adverse effects were recorded by subjects' written free recall and a symptom-checklist. Although a pharmacokinetic steady-state could be reached in sequence for the parent drug quazepam and its metabolites within 3 weeks, there was no pharmacodynamic steady-state at the end of this period, but a continuous impairment in oculomotor variables. Performance in the choice reaction task and the APTT showed a similar tendency, which was masked to a certain extend by learning effects. There were no signs for rebound effects within the 2 weeks after withdrawal. Relevant carry-over phenomena declined after 3 days of withdrawal.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-oxoquazepam,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Anxiety Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepinones,
http://linkedlifedata.com/resource/pubmed/chemical/Flurazepam,
http://linkedlifedata.com/resource/pubmed/chemical/Ro 5-3367,
http://linkedlifedata.com/resource/pubmed/chemical/quazepam
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0004-4172
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
276-83
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:2567171-Adult,
pubmed-meshheading:2567171-Anti-Anxiety Agents,
pubmed-meshheading:2567171-Benzodiazepines,
pubmed-meshheading:2567171-Benzodiazepinones,
pubmed-meshheading:2567171-Electrooculography,
pubmed-meshheading:2567171-Flurazepam,
pubmed-meshheading:2567171-Hemodynamics,
pubmed-meshheading:2567171-Humans,
pubmed-meshheading:2567171-Male,
pubmed-meshheading:2567171-Psychomotor Performance,
pubmed-meshheading:2567171-Reaction Time,
pubmed-meshheading:2567171-Respiration,
pubmed-meshheading:2567171-Substance Withdrawal Syndrome
|
pubmed:year |
1989
|
pubmed:articleTitle |
Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam.
|
pubmed:affiliation |
Institute for Pharmacodynamic Research, Munich, Fed. Rep. of Germany.
|
pubmed:publicationType |
Journal Article
|